for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aurobindo Pharma Ltd

ARBN.NS

Latest Trade

493.60INR

Change

-20.75(-4.03%)

Volume

3,731,164

Today's Range

492.20

 - 

519.00

52 Week Range

389.35

 - 

838.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
514.35
Open
515.05
Volume
3,731,164
3M AVG Volume
78.35
Today's High
519.00
Today's Low
492.20
52 Week High
838.00
52 Week Low
389.35
Shares Out (MIL)
585.90
Market Cap (MIL)
301,377.50
Forward P/E
--
Dividend (Yield %)
0.58

Next Event

Dividend For ARBN.NS - 1.7500 INR

Latest Developments

More

Aurobindo Pharma Ltd Dec Qtr Consol Profit Falls

India's Aurobindo Pharma's Unit VII Facility Classified By FDA As Official Action Indicated

Aurobindo Pharma Sept-Qtr Consol Profit Rises

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.

Contact Info

Water Mark Building,, Plot No. 11

Survey no.9, Kondapur, Hitech City

Hyderabad,Telangana

+91.40.66725000

http://www.aurobindo.com

Executive Leadership

K. Ragunathan

Non-Executive Independent Chairman of the Board

K. Nityananda Reddy

Whole-Time Vice Chairman of the Board, a promoter of the Company

Santhanam Subramanian

Chief Financial Officer

B. Adi Reddy

Compliance Officer, Company Secretary

N. Govindarajan

Managing Director, Executive Director

Key Stats

1.74 mean rating - 31 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

148.4K

2018

162.3K

2019

195.6K

2020(E)

232.3K
EPS (INR)

2017

39.330

2018

41.360

2019

41.860

2020(E)

47.070
Price To Earnings (TTM)
11.74
Price To Sales (TTM)
1.36
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
8.64
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Novartis says Zolgensma delay in Europe, Japan due to manufacturing questions from regulators

* SANDOZ Q3 OPERATING INCOME WAS USD 191 MILLION (-47%, -42% CC) IMPACTED BY CHANGES IN LEGAL SETTLEMENT PROVISIONS, HIGHER NET MANUFACTURING AND SANDOZ TRANSFORMATION RESTRUCTURING EXPENSES AND LOWER DIVESTMENT INCOME

Takeda unit sues Aurobindo to block generic Velcade

A U.S. unit of Japan's Takeda Pharmaceutical Co has sued generic drugmaker Aurobindo Pharma Ltd over its plans to make a cheaper version of Takeda's cancer drug Velcade.

Aurobindo Pharma to recall 80 lots of blood pressure medicine valsartan in the U.S.

A U.S. unit of Indian generic drugmaker Aurobindo Pharma Ltd will recall 80 lots of medicines containing blood pressure drug valsartan that were found to have a probable cancer-causing impurity, according to the U.S. Food and Drug Administration.

India's Aurobindo Pharma Q2 profit falls nearly 22 pct

Aurobindo Pharma Ltd, India's second-largest drugmaker by market capitalisation, posted a 21.7 percent fall in its second-quarter profit on Monday, hurt by higher expenses, but beat analysts' estimates.

Novartis unloads U.S. assets at loss to bargain-hunting Aurobindo

New Novartis Chief Executive Vas Narasimhan has further reshaped the Swiss drugmaker, announcing on Thursday he is selling U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd for up to $1 billion.

Novartis sells parts of Sandoz US to India's Aurobindo for $900 mln

Novartis AG said on Thursday it would sell the dermatology and generic U.S. oral solids portfolios of Sandoz U.S. to India's Aurobindo Pharma Ltd for $900 million, as the Swiss drugmaker looks to focus on higher growth areas.

BRIEF-Novartis Says To Divest Sandoz U.S. Dermatology Business And Generic U.S. Oral Solids Portfolio To Aurobindo

* NOVARTIS TO DIVEST SANDOZ US DERMATOLOGY BUSINESS AND GENERIC US ORAL SOLIDS PORTFOLIO TO AUROBINDO

BRIEF-Aurobindo Pharma Unit To Buy Commercial Ops And 3 Manufacturing Facilities From Sandoz

* UNIT AUROBINDO PHARMA USA ENTERED DEAL TO BUY COMMERCIAL OPERATIONS AND THREE MANUFACTURING FACILITIES IN USA FROM SANDOZ ., USA

India's Aurobindo Pharma Q4 profit misses estimates

India's Aurobindo Pharma Ltd posted a 0.6 percent fall in fourth-quarter net profit on Monday that missed analysts' estimates.

BRIEF-Aurobindo Pharma Says U.S. FDA Issued Form 483 With 9 Observations for Co's Unit

* AUROBINDO PHARMA LTD CLARIFIES ON NEWS ITEM ON CO'S UNIT 4 GETTING 9 OBSERVATIONS AFTER U.S. FDA INSPECTION

BRIEF-Aurobindo Pharma Says Approved Dividend Of 1 Rupee Per Share

* SAYS APPROVED SECOND INTERIM DIVIDEND OF 1 RUPEE PER SHARE Source text for Eikon: Further company coverage:

Aurobindo Pharma Q3 profit up about 3 pct, misses estimates

Aurobindo Pharma Ltd, India's third largest drugmaker by revenue, posted an about 3 percent rise in quarterly profit on Wednesday, but missed analysts' estimates.

BRIEF-India's Aurobindo Pharma Dec-Qtr Consol Net Profit Rises About 3 Pct

* DEC QUARTER CONSOL NET PROFIT 5.95 BILLION RUPEES VERSUS 5.79 BILLION RUPEES LAST YEAR

BRIEF-Aurobindo Pharma Gets U.S. FDA Approval For Fondaparinux Sodium Injection

* SAYS GETS U.S. FDA APPROVAL FOR FONDAPARINUX SODIUM INJECTION Source text - http://bit.ly/2pK1kNR Further company coverage:

BRIEF-Aurobindo Pharma Says News On Co Being Frontrunner to Buy Orchid Pharma "Factually Incorrect"

* AUROBINDO PHARMA CLARIFIES ON NEWS ITEM, "AUROBINDO, DR REDDY'S LABORATORIES FRONTRUNNERS TO BUY OUT BANKRUPT ORCHID PHARMA"

Aurobindo Pharma Q2 profit rises 29 pct, beats estimates

India's Aurobindo Pharma Ltd posted a better-than-expected 29 percent rise in quarterly profit on Thursday, helped by higher sales at its formulations business in the United States.

BRIEF-Aurobindo Pharma gets U.S. FDA nod for esomeprazole magnesium DR capsules OTC

* Says received final approval from U.S. FDA to manufacture esomeprazole magnesium delayed-release capsules OTC, 20mg

BRIEF-Aurobindo Pharma gets USFDA approval for drugs used for treatement of HIV-1 infection

* Receives USFDA tentative approval for Dolutegravir, Lamivudine & Tenofovir Disoproxil Fumarate tablets

UPDATE 1-Aurobindo Pharma Q1 profit drops 11 pct, misses estimates

Indian drugmaker Aurobindo Pharma Ltd reported a 11 percent fall in quarterly profit, hurt by lower sales from its formulations business in the U.S. and pre-launch disruptions of a pan-India tax reform.

BRIEF-India's Aurobindo Pharma June-qtr consol profit down about 11 pct

* June quarter consol net profit 5.19 billion rupees versus 5.85 billion rupees last year

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up